FDA Drug information
Praluent
Up to date, easily accessible information about drugs approved by the US Food & Drug Administration (FDA)
- Praluent ALIROCUMAB 150 mg/mL Regeneron Pharmaceuticals, Inc.
- Praluent ALIROCUMAB 150 mg/mL Sanofi US Corporation
- Praluent ALIROCUMAB 150 mg/mL Sanofi-Aventis U.S. LLC
- Praluent ALIROCUMAB 150 mg/mL Sanofi-Aventis U.S. LLC
- Praluent ALIROCUMAB 75 mg/mL Regeneron Pharmaceuticals, Inc.
- Praluent ALIROCUMAB 75 mg/mL Sanofi US Corporation
- Praluent ALIROCUMAB 75 mg/mL Sanofi-Aventis U.S. LLC
- Praluent ALIROCUMAB 75 mg/mL Sanofi-Aventis U.S. LLC
Learning Zones
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.